Method for heterologously producing ganoderic acid
By heterologously expressing an optimized enzyme system in Saccharomyces cerevisiae, we achieved the heterologous biosynthesis of ganoderic acid TR, galangalonic acid Ja, and ganoderic acid Mf, solving the problem of ganoderic acid production and providing a stable route for compound production.
Patent Information
- Application Number
- CN202411128531.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2026-03-03
AI Technical Summary
The production of ganoderic acid is difficult to achieve on a large scale, mainly due to the immaturity of Ganoderma lucidum gene manipulation, its long growth cycle, and its susceptibility to environmental factors.
By using synthetic biology techniques, candidate oxidases, reductases, and acetyltransferases were heterologously expressed in Saccharomyces cerevisiae. After codon optimization, the heterologous biosynthesis of ganoderic acid TR, galangalonic acid Ja, and ganoderic acid Mf was achieved in yeast strains.
Heterogeneous biosynthesis of ganoderic acid TR, galangalic acid Ja, and ganoderic acid Mf was achieved, solving the problem of large-scale production of ganoderic acid and providing a stable route for compound production.
Smart Images

Figure CN121592746A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to a technology in the field of bioengineering, specifically a method for heterologous production of ganoderic acid TR, galangalic acid JA, and ganoderic acid MF. Background Technology
[0002] The unique triterpenoid secondary metabolite ganoderic acid in Ganoderma lucidum cells can significantly inhibit the proliferation of various cancer cells and also possesses rich biological activities such as lowering blood pressure, protecting the liver, and anti-inflammation. However, due to the immaturity of Ganoderma lucidum gene manipulation, its long growth cycle, and its susceptibility to environmental factors (such as soil, climate, and pests), it is difficult to achieve large-scale production of ganoderic acid. Summary of the Invention
[0003] To address the aforementioned shortcomings of existing technologies, this invention proposes a method for heterologous production of ganoderic acids. By employing synthetic biology techniques to identify and utilize genes involved in the biosynthesis of ganoderic triterpenes, and then heterologously expressing these genes in Saccharomyces cerevisiae, heterologous biosynthesis of compounds such as ganoderic acid TR (GA-TR), ganoderic acid Ja (GA-Ja), and ganoderic acid Mf (GA-Mf) can be achieved.
[0004] This invention is achieved through the following technical solution:
[0005] This invention relates to a method for heterologous production of ganoderic acids. Candidate oxidases, reductases, and acetyltransferases are transformed into corresponding *Saccharomyces cerevisiae* strains for heterologous expression. The transformed strains are screened by intracellular fermentation or whole-cell catalysis to obtain codon-optimized AfuSDR and CsSDR, which catalyze the oxidation of C3 hydroxyl groups in the *Ganoderma lucidum* triterpenoid skeleton; codon-optimized reductases AKR1C2, AKR1C4, and FusC1, which catalyze the reduction of C3 keto groups; and codon-optimized acetyltransferase BsAT, which catalyzes the acetylation of C3 hydroxyl groups. These are expressed individually or in combination to achieve heterologous biosynthesis of ganoderic acid TR (GA-TR), ganoderic acid Ja (GA-Ja), and ganoderic acid Mf (GA-Mf).
[0006] The aforementioned heterologous expression refers to the direct synthesis of gene fragments into an expression vector after optimization based on the codon preferences of Saccharomyces cerevisiae.
[0007] The expression vector is plasmid pRS426-HXT7p-FBA1t-G418r, which is implemented using, but not limited to, the techniques described by XiaotingLan et al. in "Efficient biosynthesis of antitumor ganoderic acid HLDOA using a dualtunable system for optimizing the expression of CYP5150L8 and a Ganoderma P450reductase" (Biotechnol Bioeng. 2019 Dec; 116(12):3301-3311.).
[0008] The gene fragments mentioned include: AfuSDR, CsSDR, AKR1C2, AKR1C4, and FusC1.
[0009] The screening includes intracellular fermentation screening and whole-cell catalytic screening.
[0010] The intracellular fermentation screening refers to the process of introducing various expression plasmids into Saccharomyces cerevisiae through standard lithium acetate conversion, fermenting and culturing them in a culture medium, extracting the fermentation products with ethyl acetate, distilling under reduced pressure and redissolving them in methanol, observing whether new peaks are generated compared to yeast transformed with empty expression vectors, and analyzing their mass spectrometry information to determine whether the transformed gene can achieve heterologous biosynthesis.
[0011] The whole-cell catalytic screening specifically refers to: introducing each expression plasmid into yeast using the standard lithium acetate conversion method, adding the corresponding substrate after fermentation in the culture medium and continuing to culture, and then extracting the whole-cell catalytic product with ethyl acetate, distilling under reduced pressure and redissolving in methanol. By observing whether new peaks are generated and analyzing their mass spectrometry information, it is determined whether the transformed gene can achieve heterologous biosynthesis.
[0012] The standard lithium acetate conversion method described herein employs, but is not limited to, the techniques described by R Daniel Gietz et al. in "High-efficiency yeast transformation using the LiAc / SS carrier DNA / PEG method" (NatProtoc. 2007; 2(1):31-4.).
[0013] The nucleotide sequence of the codon-optimized oxidase AfuSDR is shown in Seq ID No. 1, and the amino acid sequence is shown in Seq ID No. 2; the nucleotide sequence of the codon-optimized CsSDR is shown in Seq ID No. 3, and the amino acid sequence is shown in Seq ID No. 4.
[0014] The nucleotide sequence of the codon-optimized AKR1C2 is shown in Seq ID No. 5, and the amino acid sequence is shown in Seq ID No. 6; the nucleotide sequence of the codon-optimized AKR1C4 is shown in Seq ID No. 7, and the amino acid sequence is shown in Seq ID No. 8; the nucleotide sequence of the codon-optimized FusC1 is shown in Seq ID No. 9, and the amino acid sequence is shown in Seq ID No. 10.
[0015] The optimized BsAT nucleotide sequence is shown in Seq ID No. 11, and the amino acid sequence is shown in Seq ID No. 12.
[0016] The culture medium (per liter) consists of 10 g / L yeast extract, 20 g / L beef peptone, 20 g / L glucose, and 40 g / L glycerol. Appropriate concentrations of genimycin G418 and / or hygromycin Hyg are added to the culture medium.
[0017] The brewing yeasts mentioned include: commercially available brewing yeast (S. cerevisiae) BJ5464, recombinant brewing yeast SC62, and strain SC62-CYP512W2-r.
[0018] The recombinant Saccharomyces cerevisiae SC62 refers to the genetically engineered SC62 strain (YL-T3-rDNA::eGFP-TRP1-CYP5150L8-iGLCPR), which integrates eGFP, TRP, CYP5150L8 and iGLCPR expression cassettes into the rDNA site of the genome through homologous recombination.
[0019] The strain SC62-CYP512W2-r is obtained by transforming the expression plasmid pRS426-HXT7p-CYP152W2-FBA1t-G418r into the SC62 strain. The construction method adopts, but is not limited to, the technique described by Wei Yuan et al. in "Biosynthesis of mushroom-derived type II ganoderic acids by engineered yeast" (Nat Commun. 2022 Dec 14; 13(1):7740. doi:10.1038 / s41467-022-35500-1.). Technical effect
[0020] This invention identifies, through heterologous screening, genes AfuSDR and CsSDR that catalyze the oxidation of C3 hydroxyl groups in the Ganoderma lucidum triterpenoid skeleton, genes AKR1C2, AKR1C4 and FusC1 that catalyze the reduction of C3 ketone groups, and gene BsAT that catalyzes the acetylation of C3 hydroxyl groups, thus enabling the heterologous biosynthesis of compounds such as ganoderic acid TR, galangalic acid Ja, and ganoderic acid Mf. Attached Figure Description
[0021] Figure 1 Schematic diagram of expression plasmid pRS426-HXT7p-FBA1t-G418r;
[0022] Figure 2 Schematic diagram of expression plasmid pRS426-HXT7p-AfuSDR-FBA1t-G418r;
[0023] Figure 3 Schematic diagram of expression plasmid pRS426-HXT7p-CsSDR-FBA1t-G418r;
[0024] Figure 4 Schematic diagram of expression plasmid pRS426-HXT7p-AKR1C2-FBA1t-G418r;
[0025] Figure 5 Schematic diagram of expression plasmid pRS426-HXT7p-AKR1C4-FBA1t-G418r;
[0026] Figure 6 Schematic diagram of expression plasmid pRS426-HXT7p-FusC1-FBA1t-G418r;
[0027] Figure 7 Schematic diagram of expression plasmid pRS426-HXT7p-BsAT-FBA1t-G418r;
[0028] Figure 8 Functional characterization of C3 oxidase and reductase;
[0029] Figure a: The left side of Figure a shows the HPLC analysis of fermentation extracts from strains SC62-CK-r-CYP512W2-r (CK-r-CYP512W2-r), SC62-AfuSDR-r-CYP512W2-r (Afu-r-W2-r), and SC62-CsSDR-r-CYP512W2-r (Cs-r-W2-r); the right side shows the HPLC analysis of fermentation extracts from engineered strains BJ5464-CK-r (BJ-CK-r), BJ5464-AKR1C2-r (BJ-AKR1C2-r), BJ5464-AKR1C4-r (BJ-AKR1C4-r), and BJ5464-FusC1-r (BJ-FusC1-r) after 48 hours of culture with GA-TR. Figure b shows the mass spectrometry information for GA-Jb, compound 1, and compound 2. Figure c shows the yields of GA-Jb, GA-TR, and GA-Ja after 120 h of fermentation of strains SC62-AfuSDR-AKR1C2-CYP512W2-r(Afu-C2), SC62-AfuSDR-AKR1C4-CYP512W2-r(Afu-C4), SC62-AfuSDR-FusC1-CYP512W2-r(Afu-Fu), SC62-CsSDR-AKR1C2-CYP512W2-r(Cs-C2), SC62-CsSDR-AKR1C4-CYP512W2-r(Cs-C4), and SC62-CsSDR-FusC1-CYP512W2-r(Cs-Fu). Figure d shows the biosynthetic route from GA-Jb to GA-Ja.
[0030] Figures 9-15 In order, they are glycosaminoglycan Ja (GA-Ja). 1 H-NMR, 13 C-NMR, DEPT-135, COSY, HSQC, HMBC, NOESY spectra;
[0031] Figure 16 Functional characterization of BsAT;
[0032] Figure a shows the HPLC analysis of the fermentation extracts from strains SC62-BsAT-r-CYP512W2-r (BsAT-r-W2-r) and SC62-CK-r-CYP52W2-r (CK-r-W2-r). Figure b shows the mass spectra of compounds 5 and 6. Figure c shows the ganoderic acid yield after 120 h of fermentation by strains BsAT-r-W2-r and BsAT-r-Cs-C4-W2-r. Figure d shows the hypothesized biosynthetic route from GA-Jb to GA-TO and then to GA-Mf.
[0033] Figures 17-22In order, they are ganoderic acid Mf (GA-Mf) 1 H-NMR, 13 C-NMR, DEPT-135, COSY, HSQC, and HMBC spectra. Detailed Implementation Example 1
[0034] This embodiment relates to a heterogeneous production method of GA-TR based on the separate expression of AfuSDR and CsSDR, including:
[0035] Step 1) After optimizing the sequences of the screened AfuSDR and CsSDR according to the codon preference of Saccharomyces cerevisiae, they were directly synthesized into the expression vector pRS426-HXT7p-FBA1t-G418r to obtain the oxidase expression plasmids pRS426-HXT7p-AfuSDR-FBA1t-G418r and pRS426-HXT7p-CsSDR-FBA1t-G418r.
[0036] Step 2) The oxidase expression plasmids pRS426-HXT7p-AfuSDR-FBA1t-G418r and pRS426-HXT7p-CsSDR-FBA1t-G418r, as well as the control plasmid pRS426-HXT7p-FBA1t-G418r, were transformed into yeast SC62-CYP512W2-r via the lithium acetate method. The transformed yeast was plated on SC-His-Leu-Ura-Trp (SC-HLUT) solid medium (glucose, 20 g / L; SC-His-Leu-Ura-Trp, 7.9 g / L; agar powder, 2%) for screening. After culturing at 30℃ for 2-3 days, positive transformants were selected to obtain yeast strains expressing oxidase, SC62-AfuSDR-r-CYP512W2-r and SC62-CsSDR-r-CYP512W2-r, and control strain SC62-CK-r-CYP512W2-r.
[0037] The yeast SC62-CYP512W2-r was obtained by transforming the expression plasmid pRS425-HXT7p-CYP512W2-FBA1t-G418r into yeast strain SC62.
[0038] Step 3) Inoculate the positive transformants into round-bottom test tubes containing 3 mL of SC-HLUT liquid medium and incubate for 24 h until OD. 600 The value is 2.5-4. Then, with an initial OD of 0.05... 600 Inoculated into 3mLYPD24 liquid medium (containing 200 mg / L LG418 and 200 mg / L Hyg), fermented at 30°C and 220 rpm.
[0039] Step 4) After fermentation for 120 h, take 1 mL of fermentation broth and extract twice with 800 μL of ethyl acetate. Centrifuge (12,000 g, 10 min) to collect the ethyl acetate layer, evaporate and redissolve in methanol for HPLC and LC-MS analysis.
[0040] Step 5) HPLC detection of fermentation products, specifically including: detection using an Agilent XDB-C18 analytical liquid chromatograph. Column: Agilent XDB-C18 column (4.6 μm, 5 × 150 mm); Flow rate: 1 mL / min; Injection volume: 20 μL; Detection wavelengths: 210, 245, and 225 nm; Mobile phase A: ultrapure water; Mobile phase B: methanol (containing 0.1% acetic acid); Elution program: 0-30 min, 80-100% mobile phase B; 30-35 min, 100% mobile phase B.
[0041] Step 6) LC-MS detection of fermentation products, specifically including: detection using UPLC-MS with tandem ultra-high performance liquid chromatography (UPLC) and Q-TOF mass spectrometry, with the mass spectrometry in atmospheric pressure chemical ionization (APCI) positive ion mode. Column: Waters BEHC18 column (1.7 μm, 2.1 × 100 mm); flow rate: 0.4 mL / min; injection volume: 1 μL; detection wavelengths: 210, 245, and 225 nm. Mobile phase A: ultrapure water (containing 0.1% formic acid); mobile phase B: methanol (containing 0.1% formic acid); elution program: 0-10.5 min, 70-100% mobile phase B.
[0042] Step 7) By comparing the HPLC peak chromatograms of the fermentation products with those of the control strain, it was found that AfuSDR and CsSDR could catalyze the conversion of GA-Jb, producing new peaks that were completely consistent with the retention time and mass spectrometry information of GA-TR. Figure 8 ab). That is, yeast strains SC62-AfuSDR-r-CYP512W2-r and SC62-CsSDR-r-CYP512W2-r achieved heterologous production of GA-TR. Example 2
[0043] This embodiment relates to a heterogeneous production method of GA-Ja based on the joint expression of AfuSDR, CsSDR, AKR1C2, AKR1C4, and FusC1, including:
[0044] Step 1) After optimizing the sequences of AKR1C2, AKR1C4, and FusC1 obtained from screening according to the codon preference of Saccharomyces cerevisiae, they were directly synthesized into the expression vector pRS426-HXT7p-FBA1t-G418r to obtain reductase expression plasmids pRS426-HXT7p-AKR1C2-FBA1t-G418r, pRS426-HXT7p AKR1C4-FBA1t-G418r, and pRS426-HXT7p-FusC1-FBA1t-G418r.
[0045] Step 2) The reductase expression plasmids pRS426-HXT7p-AKR1C2-FBA1t-G418r, pRS426-HXT7pAKR1C4-FBA1t-G418r, pRS426-HXT7p-FusC1-FBA1t-G418r, and the empty plasmid pRS426-HXT7p-FBA1t-G418r were transformed into yeast BJ5464 via the lithium acetate method. The transformed yeast was plated on SC-Ura solid medium (glucose, 20 g / L; SC-Ura, 7.9 g / L; agar powder, 2%) for screening. After incubating at 30℃ for 2-3 days, positive transformants were selected to obtain yeast strains expressing reductase, namely BJ5464-AKR1C2-r, BJ5464-AKR1C4-r, BJ5464-FusC1-r, and control strain BJ5464-CK-r.
[0046] Step 3) Inoculate the positive transformants into round-bottom test tubes containing 3 mL of SC-Ura liquid medium and incubate for 24 h until OD. 600 The value is 2.5-4. Then, with an initial OD of 0.05... 600 Inoculate into 3 mL of YPD24 medium (containing 300 mg / L G418), ferment at 30 °C and 220 rpm for 72 h, then add GA-TR to a final concentration of 50 μM, and culture for another 48 h.
[0047] Step 4) Extract the fermentation broth to detect metabolites, using the same method as in Example 1. HLPC and LC-MS analysis revealed that AKR1C2, AKR1C4, and FusC1 completely converted GA-TR, producing a new peak, with a major m / z of 453, an increase of 2 compared to the substrate GA-TR (m / z = 451), indicating the formation of a reduction product (…). Figure 8 ab). Later confirmed to be GA-Ja.
[0048] Step 5) Joint expression of AfuSDR, CsSDR and AKR1C2, AKR1C4, FusC1:
[0049] 5.1) Use The SoSoo Recombinant Cloning Kit was used to recombine fragments with linearized vectors according to the manufacturer's instructions. Using pRS426-HXT7p-Genes-FBA1t-G418r as a template, where Genes are AfuSDR, CsSDR, AKR1C2, AKR1C4, or FusC1, PCR amplification yielded AfuSDR, CsSDR, AKR1C2, AKR1C4, and FusC1 coding sequence fragments containing homologous arms. pRS414-TDH3p-ADH2t was linearized by PmeI digestion and recombinated with the coding sequence fragments of AfuSDR and CsSDR to obtain the oxidase helper plasmid pRS414-TDH3p-Oxidase(s)-ADH2t. pRS425-TEF1p-PGK1t-Hygr was linearized by PmeI digestion and recombinated with coding sequence fragments of AKR1C2, AKR1C4, and FusC1 to obtain the reductase helper plasmid pRS425-TEF1p-Reductase(s)-PGK1t-Hygr. The oxidase expression cassette TDH3p-Oxidase(s)-ADH2t and the reductase expression cassette TEF1p-Reductase(s)-PGK1t containing homologous arms were amplified by PCR. The two oxidases and three reductases were randomly combined to form six oxidase-reductase pairs, which were then recombinated with the EcoRI linearized expression vector pRS425-HXT7p-CYP512W2-FBA1t-Hygr.
[0050] The relevant primer sequences are shown in Table 1.
[0051] Table 1: Primer sequence list for the conjugation of C3 oxidase and reductase
[0052] F and R represent the forward and reverse primers, respectively.
[0053] 5.2) The ligation product was transformed into DH5α competent cells using traditional chemical transformation methods and plated on LB agar plates containing 100 mg / L Amp resistance. The cells were then cultured overnight at 37°C. Positive clones were picked and seeded into LB tubes containing 100 mg / L Amp resistance. The cells were then cultured overnight at 37°C and 220 rpm.
[0054] After the bacterial culture reached the stationary phase, plasmids were extracted from the *E. coli* cells, and sequencing was performed using sequencing primers to verify the results. A series of correct recombinant plasmids were obtained: pRS425-TDH3p-AfuSDR-ADH2t-TEF1p-AKR1C2-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr, pRS425-TDH3p-AfuSDR-ADH2t-TEF1p-AKR1C4-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr, and pRS425-TDH3p-AfuSDR-ADH2t-TEF1p-FusC1-PGK1t- HXT7p-CYP512W2-FBA1t-Hygr, pRS425-TDH3p-CsSDR-ADH2t-TEF1p-AKR1C2-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr, pRS425-TDH3p-CsSDR-ADH2t-TEF1p-AKR1C4-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr, and pRS425-TDH3p-CsSDR-ADH2t-TEF1p-FusC1-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr.
[0055] The sequencing primers used are shown in Table 2:
[0056] Table 2: Sequence list of sequencing primers used to verify the correctness of the plasmid combined with the oxidase-reductase pair.
[0057] 5.3) The above six recombinant plasmids were transformed into yeast SC62 by lithium acetate method. The specific method was the same as step 2 of Example 1. Six yeast strains expressing different gene combinations were obtained by screening SC-HLT (glucose, 20 g / L; SC-His-Leu-Ura-Trp, 7.9 g / L; Ura 0.1 g / L; agar powder, 2%) plates.
[0058] 5.4) Fermentation was carried out in YPD24 medium (containing 300 mg / L G418) as described in Example 1, and the metabolites were extracted and analyzed after 120 h.
[0059] 5.5) Co-expression of CsSDR and AKR1C4 produced 33.3 mg / L of compound 2 (GA-Ja), accumulated 5.4 mg / L of GA-Jb, and no GA-TR was detected. Figure 8c). In contrast, the yields of compound 2 in other strains SC62-AfuSDR-AKR1C2-CYP512W2-r, SC62-AfuSDR-AKR1C4-CYP512W2-r, SC62-AfuSDR-FusC1-CYP512W2-r, SC62-CsSDR-AKR1C2-CYP512W2-r, and SC62-CsSDR-FusC1-CYP512W2-r were only 1.3, 3.0, 1.9, 4.3, and 5.7 mg / L, respectively, with accumulated unconverted GA-Jb of 7.0, 4.3, 12.2, 14.4, and 17.9 mg / L, and GA-TR of 2.3, 0, 2.5, 11.4, and 3.2 mg / L, respectively. Figure 8 c). Therefore, strain SC62-CsSDR-AKR1C4-CYP512W2-r is the most suitable strain for production.
[0060] Step 6) Isolation, purification, and identification of the product from strain SC62-CsSDR-AKR1C4-CYP512W2-r:
[0061] 6.1) Pick colonies and incubate them in 3 mL SC-HLT medium until OD. 600 The concentration was 2.5-4, and then inoculated into 50 mL SC-HLT for seed amplification. After about 24 hours, the seed culture was inoculated into 2 L shake flasks containing 400 mL YPD24 (containing 200 mg / L LG418 and 200 mg / L Hyg) and fermented at 30 °C and 220 rpm, for a total of 5 L.
[0062] 6.2) After fermentation for 120 h, 4 L of ethyl acetate was added, and the mixture was stirred with a magnetic stirrer for 1–2 h to extract the metabolites. The entire extraction process was repeated twice. The organic layer was collected by centrifugation, and a brown extract was obtained by rotary evaporation and redissolved in 20 mL of methanol for purification.
[0063] 6.3) The first round of semi-preparative liquid phase purification is performed as follows:
[0064] Purification was performed using a preparative Agilent 1200LC system. Column: Kromasil 100-10-C18 column (20 mm × 250 mm); Flow rate: 10 mL / min; Mobile phase A: ultrapure water, Mobile phase B: methanol; Purification conditions: 0-30 min, 80-100% mobile phase B, 30-40 min, 100% mobile phase B.
[0065] Perform HPLC detection as described in step 5 of Example 1 above, combine the eluents containing the target compound, and concentrate them under reduced pressure by rotary evaporation to about 10 mL.
[0066] 6.4) Second round of semi-preparative liquid phase purification, the method is as follows:
[0067] Purification was performed using a Waters LC Prep 150 system. Column: Waters XBridge BEH C18 OBDPrep column (10 mm × 250 mm); Flow rate: 2 mL / min; Mobile phase A: ultrapure water, Mobile phase B: methanol; Purification conditions: 0-30 min, 60-100% mobile phase B, 30-40 min, 100% mobile phase B.
[0068] HPLC analysis was performed as described in step 5 of Example 1. The eluents containing the target compound and free of impurities were combined and concentrated by rotary evaporation under reduced pressure to finally obtain 5.4 mg of pure compound 2.
[0069] The structure of compound 2 was determined to be GA-Ja by nuclear magnetic resonance spectroscopy (NMR). Its carbon and proton NMR spectra are shown in Table 3. 1 H-NMR, 13 C-NMR, DEPT-135, COSY, HSQC, HMBC, and NOESY spectra are as follows: Figures 9 to 15 As shown.
[0070] Table 3: Ganoderma lucidum acid Ja (GA-Ja) 13 C-NMR and 1 HNMR data Example 3
[0071] This embodiment relates to a heterogeneous production method of GA-Mf based on BsAT-expressed GA, including:
[0072] Step 1) As described in Step 2 of Example 1, the BsAT expression plasmid pRS426-HXT7p-BsAT-FBA1t-G418 and the empty plasmid pRS426-HXT7p-FBA1t-G418r of acetyltransferase were transformed into GA-Jb yeast SC62-CYP512W2-r and GA-Ja yeast SC62-CsSDR-AKR1C4-CYP512W2-r (obtained in Example 2) using the lithium acetate method. Yeast strains expressing acetyltransferase SC62-BsAT-r-CYP512W2-r, SC62-BsAT-r-CsSDR-AKR1C4-CYP512W2-r and control strains SC62-CK-r-CYP512W2-r, SC62-CK-r-CsSDR-AKR1C4-CYP512W2-r were obtained.
[0073] Step 2) Fermentation culture and metabolic detection were performed as described in steps 3 and 4 of Example 1. By comparing the fermentation products with those of the corresponding control strains, a new peak was detected in both strains SC62-BsAT-r-CYP512W2-r and SC62-BsAT-r-CsSDR-AKR1C4-CYP512W2-r. Figure 16 a) Its fragment ion peaks include 435, 453 and 495 ( Figure 16 b) It is speculated that these are acetylated products of GA-Jb and GA-Ja, respectively, with fragment ion peaks corresponding to [M-HOAc-H2O+H]. + [M-HOAc+H] + and [M-H2O+H] + .
[0074] Step 3) To further determine the chemical structure, strain SC62-BsAT-r-CsSDR-AKR1C4-CYP512W2-r was subjected to large-scale fermentation (5L) and metabolite extraction according to step 6 of Example 2. The first round of semi-preparative purification was performed according to step 6 of Example 2. The second round of semi-preparative liquid-phase purification was performed as follows:
[0075] Purification was performed using a preparative Agilent 1200LC system. Column: Elite Hypersil ODS2 column (10 mm × 250 mm); Flow rate: 4 mL / min; Mobile phase A: ultrapure water, Mobile phase B: methanol; Purification conditions: 0-60 min, 80-100% mobile phase B, 30-40 min, 100% mobile phase B.
[0076] HPLC analysis was performed as described in step 5 of Example 1. The eluents containing the target compound and free of impurities were combined and concentrated by rotary evaporation under reduced pressure to finally obtain 14.0 mg of pure compound 4.
[0077] The structure of compound 4 was determined by NMR to be ganoderic acid Mf (GA-Mf). Its carbon and hydrogen spectral data are shown in Table 4. 1 H-NMR, 13 C-NMR, DEPT-135, COSY, HSQC, and HMBC spectra are as follows: Figures 17 to 22 As shown.
[0078] Table 4: Ganoderic acid Mf (GA-Mf) 13 C-NMR and 1 HNMR data
[0079] It has been confirmed that BsAT converts GA-Ja to GA-Mf, thus catalyzing the acetylation of the C3 hydroxyl group in the ganoderic acid skeleton. Therefore, it is inferred that BsAT can also catalyze the acetylation of the C3 hydroxyl group in GA-Jb, with new peak 3 being ganoderic acid TO (GA-TO). Figure 16 ab.d).
[0080] The above-described specific implementations can be partially adjusted by those skilled in the art in different ways without departing from the principles and purpose of the present invention. The scope of protection of the present invention is defined by the claims and is not limited to the above-described specific implementations. All implementation schemes within the scope of the claims are bound by the present invention.
Claims
1. A method for heterologous production of ganoderic acid, characterized in that, Candidate oxidases, reductases, and acetyltransferases were transformed into corresponding Saccharomyces cerevisiae strains for heterologous expression. The transformed strains were screened by intracellular fermentation or whole-cell catalysis to obtain codon-optimized AfuSDR and CsSDR, which can catalyze the oxidation of C3 hydroxyl groups in the Ganoderma triterpenoid skeleton; codon-optimized reductases AKR1C2, AKR1C4, and FusC1, which can catalyze the reduction of C3 keto groups; and codon-optimized acetyltransferase BsAT, which can catalyze the acetylation of C3 hydroxyl groups. Through single or combined expression, heterologous biosynthesis of ganoderic acid TR (GA-TR), galangaloic acid Ja (GA-Ja), and ganoderic acid Mf (GA-Mf) was achieved. The nucleotide sequence of the codon-optimized oxidase AfuSDR is shown in Seq ID No. 1, and the amino acid sequence is shown in Seq ID No. 2; the nucleotide sequence of the codon-optimized CsSDR is shown in Seq ID No. 3, and the amino acid sequence is shown in Seq ID No.
4. The nucleotide sequence of AKR1C2 after codon optimization is shown in Seq ID No. 5, and the amino acid sequence is shown in Seq ID No. 6; the nucleotide sequence of AKR1C4 after codon optimization is shown in Seq ID No. 7, and the amino acid sequence is shown in Seq ID No. 8; the nucleotide sequence of FusC1 after codon optimization is shown in Seq ID No. 9, and the amino acid sequence is shown in Seq ID No.
10. The optimized BsAT nucleotide sequence is shown in Seq ID No. 11, and the amino acid sequence is shown in Seq ID No.
12.
2. The method for heterologous production of ganoderic acid according to claim 1, characterized in that, The screening includes intracellular fermentation screening and whole-cell catalytic screening.
3. The method for heterologous production of ganoderic acid according to claim 2, characterized in that, The intracellular fermentation screening refers to the process of introducing various expression plasmids into Saccharomyces cerevisiae through standard lithium acetate conversion, fermenting and culturing them in a culture medium, extracting the fermentation products with ethyl acetate, distilling under reduced pressure and redissolving them in methanol, observing whether new peaks are generated compared to yeast transformed with empty expression vectors, and analyzing their mass spectrometry information to determine whether the transformed gene can achieve heterologous biosynthesis.
4. The method for heterologous production of ganoderic acid according to claim 2, characterized in that, The whole-cell catalytic screening specifically refers to: introducing each expression plasmid into yeast using the standard lithium acetate conversion method, adding the corresponding substrate after fermentation in the culture medium and continuing to culture, and then extracting the whole-cell catalytic product with ethyl acetate, distilling under reduced pressure and redissolving in methanol. By observing whether new peaks are generated and analyzing their mass spectrometry information, it is determined whether the transformed gene can achieve heterologous biosynthesis.
5. The method for heterologous production of ganoderic acid according to claim 1, characterized in that, The aforementioned individual expression refers to: after optimization based on the codon preference of Saccharomyces cerevisiae, directly synthesizing gene fragments AfuSDR, CsSDR, AKR1C2, AKR1C4, or FusC1 into expression vectors to obtain the corresponding oxidase expression plasmids pRS426-HXT7p-AfuSDR-FBA1t-G418r, pRS426-HXT7p-CsSDR-FBA1t-G418r, reductase expression plasmids pRS426-HXT7p-AKR1C2-FBA1t-G418r, pRS426-HXT7p-AKR1C4-FBA1t-G418r, and pRS426-HXT7p-FusC1-FBA1t-G418r.
6. The method for heterologous production of ganoderic acid according to claim 1, characterized in that, The co-expression refers to: obtaining AfuSDR, CsSDR, AKR1C2, AKR1C4, and FusC1 coding sequence fragments containing homologous arms through PCR amplification; linearizing pRS414-TDH3p-ADH2t by PmeI digestion, and recombinating it with the coding sequence fragments of AfuSDR and CsSDR to obtain the oxidase helper plasmid pRS414-TDH3p-Oxidase(s)ADH2t; linearizing pRS425-TEF1p-PGK1t-Hygr by PmeI digestion, and recombinating it with the coding sequence fragments of AKR1C2, AKR1C4, and FusC1 to obtain the reductase helper plasmid pRS425-TEF1p-Reductase(s)-PGK1t-Hygr; PCR amplification was performed on the oxidase expression cassette TDH3p-Oxidase(s)-ADH2t and the reductase expression cassette TEF1p-Reductase(s)-PGK1t, both containing homologous arms. The two oxidases and three reductases were randomly combined into six oxidase-reductase pairs, which were then recombine with the EcoRI linearized expression vector pRS425-HXT7p-CYP512W2-FBA1t-Hygr to obtain the recombinant plasmids pRS425-TDH3p-AfuSDR-ADH2t-TEF1p-AKR1C2-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr and pRS425-TDH3p-AfuSDR-ADH2t-TEF1p-AKR1C4-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr. FBA1t-Hygr, pRS425-TDH3p-AfuSDR-ADH2t-TEF1p-FusC1-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr, pRS425-TDH3p-CsSDR-ADH2t-TEF1p-AKR1C2-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr, pRS425-TDH3p-CsSDR-ADH2t-TEF1p-AKR1C4-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr, and pRS425-TDH3p-CsSDR-ADH2t-TEF1p-FusC1-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr.
7. The method for heterologous production of ganoderic acid according to any one of claims 1-6, characterized in that, The aforementioned ganoderic acid TR (GA-TR) is obtained by converting oxidase expression plasmids pRS426-HXT7p-AfuSDR-FBA1t-G418r and pRS426-HXT7p-CsSDR-FBA1t-G418r into yeast SC62-CYP512W2-r using the lithium acetate method, thereby obtaining yeast strains SC62-AfuSDR-r-CYP512W2-r and SC62-CsSDR-r-CYP512W2-r expressing oxidase, followed by fermentation culture.
8. The method for heterologous production of ganoderic acid according to any one of claims 1-6, characterized in that, The aforementioned erythrorhizonic acid Ja (GA-Ja) is obtained through: a) The reductase expression plasmids pRS426-HXT7p-AKR1C2-FBA1t-G418r, pRS426-HXT7p-AKR1C4-FBA1t-G418r, and pRS426-HXT7p-FusC1-FBA1t-G418r were transformed into yeast BJ5464 using the lithium acetate method to obtain yeast strains BJ5464-AKR1C2-r, BJ5464-AKR1C4-r, and BJ5464-FusC1-r expressing reductase. These strains were then cultured in whole cells with the substrate GA-TR added during fermentation. b) The recombinant plasmid pRS425-TDH3p-CsSDR-ADH2t-TEF1p-AKR1C4-PGK1t-HXT7p-CYP512W2-FBA1t-Hygr, which co-expresses CsSDR and AKR1C4, was transformed into yeast SC62 using the lithium acetate method to obtain the yeast strain SC62-CsSDR-AKR1C4-CYP512W2-r, which was then fermented.
9. The method for heterologous production of ganoderic acid according to claim 8, characterized in that, The aforementioned ganoderic acid Mf (GA-Mf) was obtained by transforming the acetyltransferase BsAT expression plasmid pRS426-HXT7p-BsAT-FBA1t-G418r into the GA-Ja producing yeast SC62-CsSDR-AKR1C4-CYP512W2-r using the lithium acetate method, thus obtaining the yeast strain SC62-BsAT-r-CsSDR-AKR1C4-CYP512W2-r expressing acetyltransferase, which was then fermented.
